376 related articles for article (PubMed ID: 17382711)
1. Use of urinary biomarkers for bladder cancer surveillance: patient perspectives.
Yossepowitch O; Herr HW; Donat SM
J Urol; 2007 Apr; 177(4):1277-82; discussion 1282. PubMed ID: 17382711
[TBL] [Abstract][Full Text] [Related]
2. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
Kumar A; Kumar R; Gupta NP
Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of BTA stat, cytology, and survivin in bladder cancer surveillance over 5 years in patients with spinal cord injury.
Davies B; Chen JJ; McMurry T; Landsittel D; Lewis N; Brenes G; Getzenberg RH
Urology; 2005 Oct; 66(4):908-11. PubMed ID: 16230180
[TBL] [Abstract][Full Text] [Related]
4. Potential of urinary biomarkers in early bladder cancer diagnosis.
Lam T; Nabi G
Expert Rev Anticancer Ther; 2007 Aug; 7(8):1105-15. PubMed ID: 18028019
[TBL] [Abstract][Full Text] [Related]
5. Routine surveillance cystoscopy for patients with augmentation and substitution cystoplasty for benign urological conditions: is it necessary?
Hamid R; Greenwell TJ; Nethercliffe JM; Freeman A; Venn SN; Woodhouse CR
BJU Int; 2009 Aug; 104(3):392-5. PubMed ID: 19239457
[TBL] [Abstract][Full Text] [Related]
6. Fluid intake and the risk of tumor recurrence in patients with superficial bladder cancer.
Donat SM; Bayuga S; Herr HW; Berwick M
J Urol; 2003 Nov; 170(5):1777-80. PubMed ID: 14532774
[TBL] [Abstract][Full Text] [Related]
7. Comparison of molecular and conventional strategies for followup of superficial bladder cancer using decision analysis.
Nam RK; Redelmeier DA; Spiess PE; Sampson HA; Fradet Y; Jewett MA
J Urol; 2000 Mar; 163(3):752-7. PubMed ID: 10687970
[TBL] [Abstract][Full Text] [Related]
8. Patients' perceived burden of cystoscopic and urinary surveillance of bladder cancer: a randomized comparison.
van der Aa MN; Steyerberg EW; Sen EF; Zwarthoff EC; Kirkels WJ; van der Kwast TH; Essink-Bot ML
BJU Int; 2008 May; 101(9):1106-10. PubMed ID: 17888042
[TBL] [Abstract][Full Text] [Related]
9. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity.
Kamat AM; Karam JA; Grossman HB; Kader AK; Munsell M; Dinney CP
BJU Int; 2011 Oct; 108(7):1119-23. PubMed ID: 21426474
[TBL] [Abstract][Full Text] [Related]
10. Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative?
de Bekker-Grob EW; van der Aa MN; Zwarthoff EC; Eijkemans MJ; van Rhijn BW; van der Kwast TH; Steyerberg EW
BJU Int; 2009 Jul; 104(1):41-7. PubMed ID: 19500328
[TBL] [Abstract][Full Text] [Related]
11. FGFR3 mutation analysis in voided urine samples to decrease cystoscopies and cost in nonmuscle invasive bladder cancer surveillance: a comparison of 3 strategies.
van Kessel KE; Kompier LC; de Bekker-Grob EW; Zuiverloon TC; Vergouwe Y; Zwarthoff EC; Steyerberg EW
J Urol; 2013 May; 189(5):1676-81. PubMed ID: 23142690
[TBL] [Abstract][Full Text] [Related]
12. Management of low grade papillary bladder tumors.
Herr HW; Donat SM; Reuter VE
J Urol; 2007 Oct; 178(4 Pt 1):1201-5; discussion 1205. PubMed ID: 17698090
[TBL] [Abstract][Full Text] [Related]
13. Is aneusomy of chromosome 9 alone a valid biomarker for urinary bladder cancer screening?
Panani AD; Kozirakis D; Anastasiou J; Babanaraki A; Malovrouvas D; Roussos C
Anticancer Res; 2006; 26(2A):1161-5. PubMed ID: 16619518
[TBL] [Abstract][Full Text] [Related]
14. Economic impact of tumor markers in bladder cancer surveillance.
Hong YM; Loughlin KR
Urology; 2008 Jan; 71(1):131-5. PubMed ID: 18242381
[TBL] [Abstract][Full Text] [Related]
15. uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma.
Lodde M; Mian C; Comploj E; Palermo S; Longhi E; Marberger M; Pycha A
Urology; 2006 May; 67(5):950-4. PubMed ID: 16698355
[TBL] [Abstract][Full Text] [Related]
16. [NMP-22 test. Is it useful in the follow-up of patients with superficial bladder tumor?].
Pérez García FJ; Eyo A; Escaf Barmadah S; Fernández Gómez JM
Arch Esp Urol; 2002 Dec; 55(10):1201-8. PubMed ID: 12611217
[TBL] [Abstract][Full Text] [Related]
17. Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology.
Daniely M; Rona R; Kaplan T; Olsfanger S; Elboim L; Freiberger A; Lew S; Leibovitch I
Cancer; 2007 Dec; 111(6):517-24. PubMed ID: 17963263
[TBL] [Abstract][Full Text] [Related]
18. Bladder cancer biomarkers and their role in surveillance and screening.
Van Tilborg AA; Bangma CH; Zwarthoff EC
Int J Urol; 2009 Jan; 16(1):23-30. PubMed ID: 19120523
[TBL] [Abstract][Full Text] [Related]
19. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria.
Sarosdy MF; Kahn PR; Ziffer MD; Love WR; Barkin J; Abara EO; Jansz K; Bridge JA; Johansson SL; Persons DL; Gibson JS
J Urol; 2006 Jul; 176(1):44-7. PubMed ID: 16753364
[TBL] [Abstract][Full Text] [Related]
20. Developing biomarkers for improved diagnosis and treatment outcome monitoring of bladder cancer.
Lintula S; Hotakainen K
Expert Opin Biol Ther; 2010 Aug; 10(8):1169-80. PubMed ID: 20446896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]